摘要
当今世界范围内,肺结核是世界范围内传染病的第二大致病原因。在过去的二十年中,这种疾病又开始蔓延主要是为多药耐药形式的出现。因此需要新的目标解决不断涌现的细菌耐药性和抗结核药物开发。高效的铁捕获是结核分枝杆菌的发病机制的关键,因为它作为在许多重要的生物过程,包括DNA的生物合成和细胞呼吸的辅助因子。细菌从使用铁素分枝菌素和羧基分枝杆菌素寄主获得铁螯合非血红素铁和血红素铁通过采集系统损坏红细胞释放的吸收。药物发现研究聚焦于MBTI和MBTA的抑制,这是参与分枝菌素生物合成途径的两种酶。特别是,MBTI抑制剂已在体外研究表明,在MBTA抑制剂的活性也在感染小鼠。另一类化合物,在体外和体内MmpL3抑制剂具有抗结核活性,但其作用机制似乎偏离目标。一些发现显示化合物抑制4’- phosphopantetheinyl转移酶被但未进行体内实验。本研究基于抑制剂和基因缺失的研究报告提供的数据,提出靶向铁采集系统可以被认为是一种有前途的抗结核战略。由于他们的冗余性,每个通路的结核分枝杆菌的生存的相对重要性仍需要确定。因此,在体内新的,强有力的和特定的抑制剂研究,需要突出目标选择。
关键词: 肺结核,嗜铁素,分枝菌素的生物合成, (Iso)分支酸类似物,酶抑制,铁螯合剂。
Current Medicinal Chemistry
Title:Iron Acquisition Pathways as Targets for Antitubercular Drugs
Volume: 23 Issue: 35
Author(s): Fiorella Meneghetti, Stefania Villa, Arianna Gelain, Daniela Barlocco, Laurent Roberto Chiarelli, Maria Rosalia Pasca and Luca Costantino
Affiliation:
关键词: 肺结核,嗜铁素,分枝菌素的生物合成, (Iso)分支酸类似物,酶抑制,铁螯合剂。
摘要: Tuberculosis nowadays ranks as the second leading cause of death from an infectious disease worldwide. In the last twenty years, this disease has again started to spread mainly for the appearance of multi-drug resistant forms. Therefore, new targets are needed to address the growing emergence of bacterial resistance and for antitubercular drug development. Efficient iron acquisition is crucial for the pathogenesis of Mycobacterium tuberculosis, because it serves as cofactor in many essential biological processes, including DNA biosynthesis and cellular respiration. Bacteria acquire iron chelating non-heme iron from the host using the siderophore mycobactins and carboxymycobactins and by the uptake of heme iron released by damaged red blood cells, through several acquisition systems. Drug discovery focused its efforts on the inhibition of MbtI and MbtA, which are are two enzymes involved in the mycobactin biosynthetic pathway. In particular, MbtI inhibitors have been studied in vitro, while MbtA inhibitors showed activity also in infected mice. Another class of compounds, MmpL3 inhibitors, showed antitubercular activity in vitro and in vivo, but their mechanism of action seems to be off-target. Some compounds inhibiting 4’-phosphopantetheinyl transferase were discovered but not tested on in vivo assays. The available data reported in this study based on inhibitors and gene deletion studies, suggest that targeting iron acquisition systems could be considered a promising antitubercular strategy. Due to their redundancy, the relative importance of each pathway for Mycobacterium tuberculosis survival has still to be determined. Thus, in vivo studies with new, potent and specific inhibitors are needed to highlight target selection.
Export Options
About this article
Cite this article as:
Fiorella Meneghetti, Stefania Villa, Arianna Gelain, Daniela Barlocco, Laurent Roberto Chiarelli, Maria Rosalia Pasca and Luca Costantino , Iron Acquisition Pathways as Targets for Antitubercular Drugs, Current Medicinal Chemistry 2016; 23 (35) . https://dx.doi.org/10.2174/0929867323666160607223747
DOI https://dx.doi.org/10.2174/0929867323666160607223747 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NMR Assisted Antimicrobial Peptide Designing: Structure Based Modifications and Functional Correlation of a Designed Peptide VG16KRKP
Current Medicinal Chemistry Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy A Review of Antimycobacterial Drugs in Development
Mini-Reviews in Medicinal Chemistry Helicobacter pylori: An Overview on Antimicrobials and Drug Delivery Systems for its Eradication
Current Drug Delivery Key Amino Acids of Arabidopsis VKOR in the Activity of Phylloquinone Reduction and Disulfide Bond Formation
Protein & Peptide Letters Riboflavin Analogs as Antiinfectives: Occurrence, Mode of Action, Metabolism and Resistance
Current Pharmaceutical Design Targeting TNF-Alpha in HIV-1 Infection
Current Drug Targets Sulfonamides as Potential Bioactive Scaffolds
Current Organic Chemistry Mechanism of Conjugated Imine and Iminium Species, including Marine Alkaloids: Electron Transfer, Reactive Oxygen Species, Therapeutics and Toxicity
Current Bioactive Compounds Editorial (Thematic Issue: <i>In Silico</i> Drug Design and Medicinal Chemistry)
Current Topics in Medicinal Chemistry Cycloserine Induced Suicidal Tendencies and Kanamycin Induced Ototoxicity in Indian MDR-TB Patient: A Case Report
Current Drug Safety Docking Studies for Multi-Target Drugs
Current Drug Targets Antibiotics with Antiviral and Anti-Inflammatory Potential Against Covid-19: A Review
Current Reviews in Clinical and Experimental Pharmacology Microwave-Assisted Synthesis of Pyrazinamide Derivatives: The Coupling Reaction of 3-Chloropyrazine-2-Carboxamide and Ring-Substituted Anilines
Current Organic Synthesis Managing Febrile Illness in Malaria-endemic Areas: Developing Novel Diagnostics Using Host Immunological Signatures as Surrogate Markers of Infection
Current Immunology Reviews (Discontinued) Do You See What I See: Recognition of Protozoan Parasites by Toll-Like Receptors
Current Immunology Reviews (Discontinued) An Efficient and Environmentally Benign Four-component Domino Protocol for Synthesis of Spirooxindoles Spiroannulated with Fused Heterosystems of Privileged Heterocycles
Current Bioactive Compounds In-Situ Formation of Liposome of Rifampicin: Better Availability for Better Treatment
Current Drug Delivery Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety
Letters in Drug Design & Discovery A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism